Haberthür C, Pless M, Tichelli A, Gratwohl A, Speck B, Betticher D C
Departement Innere Medizin, Kantonsspital Basel.
Schweiz Med Wochenschr. 1994 Jan 11;124(1-2):73-8.
We report the case of a 70-year-old patient with B-cell chronic lymphocytic leukemia. During therapy with the new purine analog 2-chloro-deoxyadenosine (2-CDA) the patient developed Pneumocystis carinii pneumonia (PCP). Although the mechanism of action of 2-CDA suggests the incidence of opportunistic infections and therefore pneumocystis pneumonia, this is the first case of PCP among 140 patients of the Swiss study of 2-CDA. The mechanism of action of 2-CDA is described and the occurrence of PCP among patients without acquired immunodeficiency syndrome is discussed.
我们报告了一例70岁的B细胞慢性淋巴细胞白血病患者。在使用新型嘌呤类似物2-氯脱氧腺苷（2-CDA）治疗期间，该患者发生了卡氏肺孢子虫肺炎（PCP）。尽管2-CDA的作用机制提示机会性感染包括肺孢子虫肺炎的发生率，但这是瑞士2-CDA研究中140例患者中的首例PCP病例。本文描述了2-CDA的作用机制，并讨论了在无获得性免疫缺陷综合征患者中发生PCP的情况。
